

REMARKS

Status of the Claims.

Claims 1, 3-5, 7-19, and 22-32 are pending with entry of this amendment, claims 2, 6, 20, and 21 being cancelled and no claims being added. Claims 5, 17, and 24 are amended to correct typographic errors.

Claim Objections

Claims 6 and 21 were objected to under 37 C.F.R. §1.75(c) as allegedly being of improper dependent form for failing to further limit the subject matter of a previous claim. Claims 6 and 21 are canceled herein thereby obviating this objection.

Claims 5 and 24 were objected to because of the recitation of the word "apoprotein" instead of "apoprotein". Claim 17 was objected to because of the recitation of "an-apoprotein". Claims 5, 17, and 24 are amended herein to obviate these objections.

Obviousness-Type Double Patenting.


Claims 1, 3, 9-21, and 27-31 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4, 6-7, 9-11, 13-16, 19, 21-22, and 24-26 of U.S. Patent No: 6,014,014. A properly executed Terminal Disclaimer is provided herewith, thereby obviating this rejection.

In view of the foregoing, Applicants believes all claims now pending in this application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested. Should the Examiner seek to maintain the rejections, Applicants request a telephone interview with the Examiner and the Examiner's supervisor.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 769-3513.

QUINE INTELLECTUAL PROPERTY LAW
GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
Tel: 510 337-7871
Fax: 510 337-7877

Respectfully submitted,



Tom Hunter
Reg. No: 38,498